Takeda inks discovery pact with Stanford; Jounce taps Ariad vet Cole as new CBO

Takeda’s research group in Cambridge, MA has struck a deal to work more closely with researchers at Stanford with an eye to moving more drugs through R&D. “Takeda’s alliance with Stanford demonstrates our commitment to advancing medicines as quickly and efficiently as possible – from drug discovery to development and ultimately to patients,” said Juan Harrison, vice president, head of strategic academic alliances, Takeda.

⇨ Cambridge, MA-based Jounce Therapeutics $JNCE has picked Ariad vet Hugh Cole as its new chief business officer and head of corporate development. Cole is credited with doing nine deals for Ariad.

⇨ The microcap biotech Tracon Pharmaceuticals touted new Phase I/II data from a small, single-arm study combining TRC105 and Nexavar (sorafenib) in hepatocellular cancer. The dose-ranging study included 26 patients, with an ORR of 25%; 33% if you just look at the two top doses.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->